Oral GLP-1 (semaglutide) option for patients who prefer a tablet over injections. Doctor-prescribed and delivered nationwide.
Rybelsus contains semaglutide in an oral tablet form. It offers the metabolic and appetite-suppressing benefits of GLP-1 therapy without weekly injections — ideal for patients who prefer oral dosing.
Semaglutide acts on appetite and metabolic pathways to reduce hunger, improve glucose control and support sustainable weight loss when used under medical guidance.
Rybelsus is suitable for adults who need GLP-1 treatment but prefer non-injectable therapy. A doctor review is mandatory to confirm medical suitability.
When prescribed and monitored by a doctor, Rybelsus is safe. Our team screens for contraindications and provides follow-up.
Many patients notice reduced appetite in 2–4 weeks; measurable weight loss typically appears by 6–12 weeks.